BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 23059146)

  • 21. The Influence of the CYP3A4*22 Polymorphism and CYP2D6 Polymorphisms on Serum Concentrations of Aripiprazole, Haloperidol, Pimozide, and Risperidone in Psychiatric Patients.
    van der Weide K; van der Weide J
    J Clin Psychopharmacol; 2015 Jun; 35(3):228-36. PubMed ID: 25868121
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine.
    Brynne N; Dalén P; Alván G; Bertilsson L; Gabrielsson J
    Clin Pharmacol Ther; 1998 May; 63(5):529-39. PubMed ID: 9630826
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.
    Laine K; Tybring G; Härtter S; Andersson K; Svensson JO; Widén J; Bertilsson L
    Clin Pharmacol Ther; 2001 Oct; 70(4):327-35. PubMed ID: 11673748
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Psychotropic medications and cytochrome P450 2D6: pharmacokinetic considerations in the elderly.
    Shulman RW; Ozdemir V
    Can J Psychiatry; 1997 Jun; 42 Suppl 1():4S-9S. PubMed ID: 9220124
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics of dextromethorphan after single or multiple dosing in combination with quinidine in extensive and poor metabolizers.
    Pope LE; Khalil MH; Berg JE; Stiles M; Yakatan GJ; Sellers EM
    J Clin Pharmacol; 2004 Oct; 44(10):1132-42. PubMed ID: 15342614
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum dextromethorphan/dextrorphan metabolic ratio for CYP2D6 phenotyping in clinical practice.
    Jurica J; Bartecek R; Zourkova A; Pindurova E; Sulcova A; Kasparek T; Zendulka O
    J Clin Pharm Ther; 2012 Aug; 37(4):486-90. PubMed ID: 22548589
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CYP2D6 predicted metabolizer status and safety in adult patients with attention-deficit hyperactivity disorder participating in a large placebo-controlled atomoxetine maintenance of response clinical trial.
    Fijal BA; Guo Y; Li SG; Ahl J; Goto T; Tanaka Y; Nisenbaum LK; Upadhyaya HP
    J Clin Pharmacol; 2015 Oct; 55(10):1167-74. PubMed ID: 25919121
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects.
    Dezentjé VO; Opdam FL; Gelderblom H; Hartigh den J; Van der Straaten T; Vree R; Maartense E; Smorenburg CH; Putter H; Dieudonné AS; Neven P; Van de Velde CJ; Nortier JW; Guchelaar HJ
    Breast Cancer Res Treat; 2015 Oct; 153(3):583-90. PubMed ID: 26369533
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response.
    Gex-Fabry M; Eap CB; Oneda B; Gervasoni N; Aubry JM; Bondolfi G; Bertschy G
    Ther Drug Monit; 2008 Aug; 30(4):474-82. PubMed ID: 18641553
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CYP2D6 genotype affects age-related decline in flecainide clearance: a population pharmacokinetic analysis.
    Doki K; Homma M; Kuga K; Aonuma K; Kohda Y
    Pharmacogenet Genomics; 2012 Nov; 22(11):777-83. PubMed ID: 22941032
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity.
    Hamelin BA; Bouayad A; Méthot J; Jobin J; Desgagnés P; Poirier P; Allaire J; Dumesnil J; Turgeon J
    Clin Pharmacol Ther; 2000 May; 67(5):466-77. PubMed ID: 10824625
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment.
    Brockmöller J; Kirchheiner J; Schmider J; Walter S; Sachse C; Müller-Oerlinghausen B; Roots I
    Clin Pharmacol Ther; 2002 Oct; 72(4):438-52. PubMed ID: 12386646
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics.
    Kirchheiner J; Heesch C; Bauer S; Meisel C; Seringer A; Goldammer M; Tzvetkov M; Meineke I; Roots I; Brockmöller J
    Clin Pharmacol Ther; 2004 Oct; 76(4):302-12. PubMed ID: 15470329
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Respective Roles of CYP3A4 and CYP2D6 in the Metabolism of Pimozide to Established and Novel Metabolites.
    Chapron BD; Dinh JC; Toren PC; Gaedigk A; Leeder JS
    Drug Metab Dispos; 2020 Nov; 48(11):1113-1120. PubMed ID: 32847865
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Utilization of pharmacogenomics and therapeutic drug monitoring for opioid pain management.
    Jannetto PJ; Bratanow NC
    Pharmacogenomics; 2009 Jul; 10(7):1157-67. PubMed ID: 19604091
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics of novel atrial-selective antiarrhythmic agent vernakalant hydrochloride injection (RSD1235): influence of CYP2D6 expression and other factors.
    Mao ZL; Wheeler JJ; Clohs L; Beatch GN; Keirns J
    J Clin Pharmacol; 2009 Jan; 49(1):17-29. PubMed ID: 18927241
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CYP2D6 polymorphisms and codeine analgesia in postpartum pain management: a pilot study.
    VanderVaart S; Berger H; Sistonen J; Madadi P; Matok I; Gijsen VM; de Wildt SN; Taddio A; Ross CJ; Carleton BC; Hayden MR; Koren G
    Ther Drug Monit; 2011 Aug; 33(4):425-32. PubMed ID: 21743374
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetic and pharmacodynamic interactions between metoprolol and dronedarone in extensive and poor CYP2D6 metabolizers healthy subjects.
    Damy T; Pousset F; Caplain H; Hulot JS; Lechat P
    Fundam Clin Pharmacol; 2004 Feb; 18(1):113-23. PubMed ID: 14748763
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CYP2D6 Genetic Polymorphisms and Risperidone Pharmacokinetics: A Systematic Review and Meta-analysis.
    Zhang L; Brown SJ; Shan Y; Lee AM; Allen JD; Eum S; de Leon J; Bishop JR
    Pharmacotherapy; 2020 Jul; 40(7):632-647. PubMed ID: 32519344
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intermediate metabolizer: increased side effects in psychoactive drug therapy. The key to cost-effectiveness of pretreatment CYP2D6 screening?
    Laika B; Leucht S; Heres S; Steimer W
    Pharmacogenomics J; 2009 Dec; 9(6):395-403. PubMed ID: 19451914
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.